|

Allogeneic CD34+-enriched and CD45RA-depleted PBSCs Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Allogeneic TN-depleted CD34-preserved PBSCs, Allogeneic TND- CD34+ PBSCs, Donor-derived TN Cell Depleted CD34-enriched PBSCs, Naive T-cell Depleted CD34+ Allogeneic Peripheral Blood Stem Cells

Pipeline

Phase 2: 1

Top Sponsors

  • Fred Hutchinson Cancer Center1

Indications

  • Acute Leukemia1
  • Myeloproliferative Neoplasm1
  • Myelodysplastic Syndrome1
  • Acute Myeloid Leukemia1
  • Acute Lymphoblastic Leukemia1

Tampa, Florida1 trial

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Moffitt Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.